

A provider's guide to helping patients save on Mestinon (Pyridostigmine). Covers pricing, assistance programs, generics, and cost conversation strategies.
When patients can't afford their medications, they don't take them. For patients on Mestinon (Pyridostigmine Bromide), medication cost and availability are increasingly becoming barriers to consistent treatment — particularly for the extended-release formulation, which has seen both supply shortages and significant price increases.
As a prescriber, you're in a unique position to help patients navigate cost challenges before they lead to missed doses, disease flares, or emergency department visits. This guide provides a practical framework for identifying savings opportunities and integrating cost conversations into your clinical workflow.
Understanding the cost landscape helps you anticipate which patients may need financial assistance:
The cost differential between the IR and ER formulations is substantial. Patients taking the ER formulation — especially those paying cash or with high-deductible plans — are at the highest risk for cost-related nonadherence.
Bausch Health, the manufacturer of brand-name Mestinon, does not currently offer a specific copay savings card for Mestinon. However, they do offer a Patient Assistance Program (PAP):
For patients who don't qualify for the PAP, the generic versions are almost always the more cost-effective route.
Discount cards can significantly reduce out-of-pocket costs for uninsured patients or those with high copays. These are free to use and accepted at most pharmacies:
A practical tip: recommend that patients compare prices across 2–3 discount platforms, as pricing varies by pharmacy and can change week to week. Medfinder for Providers can also help you and your staff quickly check availability and pricing.
Since generic Pyridostigmine is available, cost-based therapeutic substitution is primarily relevant when patients can't access a specific formulation:
If a patient can't afford or find the ER 180 mg formulation, switching to the IR 60 mg tablets taken in divided doses is a clinically reasonable alternative. The IR version is more available and significantly cheaper. The trade-off is a more complex dosing schedule (every 4–6 hours vs. once or twice daily), which may affect adherence differently depending on the patient.
When making this switch, consider:
If Pyridostigmine is unavailable or poorly tolerated, limited alternatives exist:
For a complete overview of alternatives, see our clinical alternatives guide.
Research consistently shows that patients rarely bring up medication costs on their own. Proactively addressing cost can improve adherence and outcomes:
Consider adding a standardized note template for cost discussions:
Medication cost shouldn't be the reason a myasthenia gravis patient has a flare. With generic Pyridostigmine widely available at $26–$50 for the IR formulation, most patients can afford treatment — but only if they know about discount cards, assistance programs, and the cost differences between formulations.
As a prescriber, a two-minute conversation about cost at the point of prescribing can prevent weeks of nonadherence down the line. And tools like Medfinder for Providers make it easy to check stock and help patients fill their prescriptions without delays.
For the patient-facing version of this information, see our patient savings guide for Mestinon.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.